Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (103)	11/12/2001 10:55:04 AM
From: tuck	Read Replies (1) \| Respond to of 254

>>MARLBOROUGH, Mass.--(BW HealthWire)--Nov. 12, 2001--Cetek Corporation announced today that it has signed an agreement with Lexicon Genetics Incorporated (Nasdaq:LEXG - news) to develop assays and perform high throughput screens against several novel in vivo validated targets for the discovery of lead compounds from Lexicon's high quality compound libraries. Financial terms were not disclosed. ``Lexicon Genetics is a first-class, target-rich drug discovery company that has built a leading franchise in functional genomics,'' said James. L. Waters, President of Cetek. ``We are pleased that Lexicon Genetics recognizes the importance of our CE assay technology and screening expertise, and we look forward to identifying several promising lead compounds from Lexicon's libraries that can advance into development.'' Cetek has demonstrated that its core CE Assay is able to efficiently identify and rank the affinity of synthetic and natural product small molecules to therapeutic target proteins in a high-throughput environment. Cetek has screened over 6 million compounds against 120 targets in the last two years of operation. Cetek has doubled its screening capacity over the last three months to accommodate increased demand in contract screening and to accommodate demand from the Cetek Natural Products program. Ongoing screening collaborations at Cetek include: Pharmacia, Genome Therapeutics, Millennium Pharmaceuticals, Microcide Pharmaceuticals, Johnson & Johnson and Schering-Plough plus others in North America, Europe and Japan.<< snip Cheers, Tuck